Global demand for high-end medical devices is being shaped by aging populations and rising chronic disease rates, creating durable, long-term needs. The fusion of digital and intelligent technologies is transforming product designs and reshaping the competitive arena, while the supply side is steadily progressing toward higher technological sophistication and greater domestic leadership. Research and development in medical equipment is transitioning from an imitative to an independent innovation phase, supported by a growing portfolio of invention patents and strong sector-wide momentum.
Nevertheless, weaknesses persist in the supply chain, with dependence on foreign sources for certain core components. Established international leaders maintain market dominance through decades of accumulated technical expertise. Domestic competitors, in turn, are pursuing breakthroughs through differentiated strategies.
In terms of credit, the sector exhibits robust financing activity in technology innovation, with private enterprises serving as the primary bond issuers. The overall credit spread for the industry narrowed in the first half of 2026 compared to the previous year. Looking forward, as the impact of centralized procurement policies subsides and innovative products enter their commercial scaling phase, the sector is transitioning from quantitative accumulation to qualitative breakthroughs. This shift is ushering in a more favorable growth cycle. Medium-to-long-term credit fundamentals are expected to remain stable, though structural risks will persist for weaker entities lacking sufficient capacity to commercialize innovation.
Supply Capacity Analysis
The global high-end medical device market is at a critical stage of transformation, moving from phase-based growth toward a deeper, internally driven restructuring. Market size continues to expand, and the deep integration of digital and intelligent technologies is redefining product forms and the competitive structure. Emerging fields such as surgical robotics and AI-assisted diagnostics are becoming new engines of industry growth.
Within the industry chain, medical devices occupy the midstream segment, where core components, key materials, and electronic elements are integrated and assembled into final products. By product type, the sector is categorized into medical consumables (both high-value and low-value), medical equipment, and in-vitro diagnostics. High-end devices encompass medical equipment characterized by high technological barriers, intensive intellectual property, substantial R&D investment, and significant clinical value. This category includes advanced imaging systems, surgical robots, AI-based devices, and novel biomaterial-based instruments.
Global market expansion is propelled by rising chronic disease prevalence, accelerated population aging, and growing demand for biopharmaceuticals and precision medicine. According to IIM data, the global high-end medical device market reached $487 billion in 2025, a 34.6% increase from 2020. China's share accounted for 32.4% of the global total.
This transformation phase is marked by significant technological convergence. Capital-intensive hardware is becoming deeply intertwined with data-driven software, as digitalization and intelligence reshape product offerings and competitive dynamics. The development landscape is bifurcated: high-end innovative segments grow rapidly, mature sectors progress steadily, and basic consumables expand at a slower pace. Frontier areas like surgical robots and AI-assisted diagnostics are experiencing fast technological iteration and vast clinical potential. In 2025, global sales of AI-assisted diagnostic software reached $1.876 billion and are projected to hit $4.298 billion by 2032, a compound annual growth rate of 12.4%, according to QYResearch. Meanwhile, the global surgical robot market was valued at $24.77 billion in 2025, growing at a 24.4% CAGR from 2020 to 2025, as reported by Puhua Youce.
Domestically, the number of medical device manufacturers and registered products continues to grow steadily. However, structural differentiation is pronounced. Companies capable of producing higher-risk Class III devices are exhibiting strong expansion momentum, and the growth rate of domestic Class III product registrations significantly outpaces that of imported products. The supply side is improving in terms of both technological sophistication and domestic dominance.
From 2021 to 2025, the number of medical device manufacturers in China increased from 28,800 to 35,800, a CAGR of approximately 5.6%, according to the High-end Medical Device Industry Data Center. Based on risk classification, products are divided into three categories. In 2025, the number of enterprises producing Class I, II, and III products reached 24,300, 17,900, and 3,400, respectively, with growth rates of 6.90%, -0.43%, and 7.83%. While most companies are positioned in lower-tech segments, the number of firms handling higher-risk Class III devices saw a 16.67% growth in 2024, sustaining its pace into 2025. This demonstrates accelerating expansion among high-end manufacturers and a shift toward more sophisticated production.
Registered product volumes expanded from 2021 to 2025. In 2025, domestic Class I devices accounted for over 50% of the total product mix, maintaining a dominant market position. Although Class III products represent a smaller share, domestic Class III registrations increased by 12.03% year-on-year, while imported products fell by 2.58%. This trend indicates a progressive shift toward a domestically led product structure.
Approval processes for innovative devices are accelerating. In 2025, the National Medical Products Administration approved 76 innovative medical devices, a 16.9% increase, and 25 priority-reviewed devices, a 212.5% surge. Approvals spanned fields such as AI, cancer radiotherapy, and biomedical materials. Among approved innovative devices, 61% were active products and 32% were passive products, with concentration in electromechanical equipment and high-value implantable consumables. Decision-support software maintained a stable presence in software-based devices, while imaging processing software grew from 5 products in 2023 to 8 in 2025, and treatment planning software increased from 1 to 7 products. Surgical robot product numbers rose from 39 in 2023 to 62 in 2025, reflecting a robust improvement in supply capacity.
Export structures are also upgrading. In 2025, medical device exports reached $50.469 billion, up 3.54% year-on-year, according to the China Chamber of Commerce for Import and Export of Medicines & Health Products. Hospital diagnostics and treatment products led with $24.057 billion in exports, an 8.12% increase, accounting for 47.67% of the total. Disposable consumables contributed $10.911 billion, up 3.77%. Notably, exports of PET and SPECT imaging equipment surged 175.2%, and surgical robots grew 368.1%, underscoring rapid technological advances and growing global recognition of Chinese high-end medical equipment. Additional growth was seen in X-ray scanners, MRI systems, artificial kidneys, endoscopes, and artificial joints, based on iFinD data.
Supply resilience presents a mixed picture. While the domestic industry has developed comprehensive capabilities in mid-to-low-end complete machines and general components, vulnerabilities persist in high-end sectors. Critical components remain reliant on imports, exposing the supply chain to risks from overseas production fluctuations, cross-border logistics disruptions, and export controls. Moreover, the stringent precision and consistency requirements for high-end devices mean that even successful prototypes face extended timelines to achieve stable mass production. These constraints limit the speed and scale of capacity expansion, underscoring the need to strengthen supply chain security.
Demand Matching Capacity Analysis
Demand for medical devices is fundamentally rigid and largely insulated from economic cycles. It originates from deepening population aging and the persistent pursuit of superior healthcare services, granting the sector a distinctly counter-cyclical quality. According to the UN's 2025 World Population Prospects, the global share of people aged 65 and above is projected to rise from 10% in 2025 to nearly 20% by 2050. In China, the population aged 65 and over reached 223.65 million by the end of 2025, representing 15.92% of the total. This aging trend, coupled with the rising and increasingly younger onset of chronic diseases, directly drives demand for equipment used in complex critical care scenarios, such as cardiovascular interventions and neuromodulation.
In 2025, the global demand for high-end medical devices totaled $458 billion, up 6.5% year-on-year, per IIM data. Oncology diagnostic and treatment equipment, cardiovascular devices, and neuroscience devices accounted for 24.45%, 21.40%, and 8.95% of this demand, respectively, making these the core clinical applications driving the market.
Domestic demand exhibits multi-tiered growth and geographic expansion. According to Zhongcheng Digital Science-MDBIDS, the scale of China's medical device public tender and procurement market increased by 30.14% in 2025. Procurement is concentrated in the eastern and western regions, though central China saw exceptional growth of over 50%. Tertiary hospitals remained the primary purchasers, accounting for 62.08% of procurement and growing 36.26% year-on-year. Primary and secondary hospitals also grew by over 10%, spurred by the tiered diagnosis and treatment system and resource decentralization. Market shares for CT, ultrasound diagnostic equipment, and surgical robots increased in 2025. Penetration rates for surgical robots, wearable monitoring devices, and AI-assisted diagnostic systems were 18%, 22%, and 34%, respectively, in 2025, and are expected to reach 35%, 41%, and 58% by 2030.
The industry operates in a state of dynamic equilibrium between expanding demand and structural supply upgrades. While overall supply capacity is improving, gaps remain in high-performance products within frontier segments like advanced imaging, surgical robotics, and high-end implants. Domestic registration progress varies significantly across sectors, and several high-barrier categories have yet to achieve domestic registration. Performance gaps and differences in procurement budgets and application scenarios across hospital levels mean some high-end demand is still met by imports. Equilibrium is gradually restored through product iteration and the import substitution process.
Position in the Industry Chain
Upstream suppliers of specialty materials and core components hold pricing power due to high technological barriers. Downstream, tertiary hospitals are the primary purchasers, and centralized procurement policies bolster their bargaining leverage. Midstream manufacturers thus face pressure from both ends, leaving them with limited pricing flexibility.
Raw materials, including medical metals, polymers, and bioceramics, are fundamental to high-value consumables and implants. Strict requirements for biocompatibility, mechanical strength, and corrosion resistance, coupled with limited supplier numbers, give upstream players significant pricing power. Core components for imaging, IVD, and surgical robots are technically complex and require exceptional precision. While domestic substitution has advanced for many parts, high-end components critical to reliability remain import-dependent, with suppliers dominating pricing.
Downstream, procurement is concentrated in tertiary hospitals. The volume-based procurement policy has increased hospital bargaining leverage by linking volume to price and expanding product selection options. Midstream manufacturers face rising material costs amid import dependence and price reductions from procurement, with a common trade-off of lower prices for higher volume. The sector is characterized by a clear divide: leading firms with strong R&D and branding maintain competitiveness, while many smaller players in lower-tech segments struggle with product homogeneity. Those with proprietary technologies and differentiated products can sustain relative pricing power on the sales side.
The global competitive landscape is defined as "high barriers in premium segments, rising forces in emerging markets." North American firms, backed by capital strength, FDA registration systems, and extensive clinical data, dominate most high-end markets. German and Swiss companies excel in precision manufacturing. Asia-Pacific, driven by China, is a key emerging growth region, while South America, the Middle East, and Africa depend largely on basic device imports. Leading overseas players protect their dominance through four competitive bulwarks: technical know-how, patents, clinical resources, and distribution channels.
Among listed sample companies involved in high-end devices, 2025 performance showed marked divergence. In the in-vitro diagnostics sector, ongoing centralized procurement and price governance reforms led to adjustment pressures. Mindray Medical retained the top revenue position but saw both revenue and net profit decline due to DRG/DIP payment reforms, hospital operating pressures, and procurement policies. Conversely, United Imaging demonstrated resilience with both revenue and profit growth, driven by domestic substitution and gained market share in CT and other high-end imaging systems. In surgical robotics, Shanghai MicroPort MedBot achieved doubled revenue, propelled by commercial breakthroughs with its Toumai laparoscopic robot and successful overseas expansion. However, due to long development cycles, extensive clinical trials, and substantial upfront investment, most robotic firms remain unprofitable. In the consumables sector, overall growth persisted, with companies like Shenzhen Huatai Biomedical and Beijing Bairong Medical achieving synchronized revenue and profit growth through differentiated products such as coronary access devices and bioprosthetic heart valves.
Price Dynamics
High-end medical device prices exhibit clear structural differentiation. Mature categories face pricing pressure, while innovative premium segments display stronger resilience. Over the long term, pricing logic is shifting from pure competition on price to a focus on clinical value, with innovation becoming a critical support for maintaining pricing power and profitability.
Key drivers of price trends include centralized procurement, import substitution progress, core component costs, and hospital payment capacity. For advanced, high-barrier equipment like high-end MRI, PET-CT, and surgical robots, imported products have long commanded premium prices. As domestic alternatives reach the market, reasonable price corrections occur, but significant price drops are unlikely due to high R&D costs and rigid procurement expenses. In contrast, some IVD products included in procurement have seen sharp price reductions, compressing profit margins.
Net profits in the medical equipment segment fell from RMB 22.081 billion in 2023 to RMB 15.098 billion in 2025, with gross margins declining from 51.53% to 48.36%. The medical consumables segment saw profits decrease to RMB 9.677 billion by 2025. The IVD segment experienced a more dramatic decline in net profit, from RMB 8.798 billion to RMB 3.223 billion, with margins easing to 60.30%. The Shenwan Medical Device Index, after a prolonged descent since 2021, shows signs of stabilizing but has not yet established a clear turning point. Price recovery is contingent on sustained innovation and import substitution.
Import prices for MRI systems remain high and trending upward, driven by incomplete substitution of top-tier imported models and higher tariffs on core components. Chinese exports remain predominantly mid-to-low-end, with export unit prices for certain high-end devices significantly below import prices. Cost pressures from imported specialty materials and components pass through to final product pricing. Amid healthcare cost controls and DRG/DIP reforms, downstream purchasing constraints are tightening, pushing companies to adjust pricing strategies. Overall, the sector is not experiencing broad-based price deflation but rather a bifurcated pattern: mature products face downward pressure, while innovative, high-end products maintain pricing resilience. Firms with core technological advantages possess stronger pricing power, whereas those with commoditized, easily substitutable offerings face significant price competition.
Innovation Capacity Analysis
Policy frameworks are actively fostering innovation, with new quality productive forces unlocking opportunities in brain-computer interfaces and high-end medical devices. The 15th Five-Year Plan explicitly lists brain-computer interfaces and high-end devices as new industries to cultivate, calling for breakthroughs in key technologies such as electrodes and specialized chips, and promoting applications in neurological disease treatment and rehabilitation. It also prioritizes the development and scaled deployment of ultra-high-end CT scanners, high-resolution MRI, radiotherapy systems, and intelligent surgical robots, alongside novel implantable interventional devices for chronic disease management, neural stimulation, and cardiovascular and orthopedic care.
In July 2025, seven ministries issued implementation guidelines on advancing brain-computer interface innovation, targeting the initial establishment of a robust technical, industrial, and standards system by 2027. In October 2025, guidelines on promoting and regulating AI plus healthcare applications were released, focusing on intelligent medical equipment innovation and supporting first-of-a-kind domestic deployments in hospitals. In March 2026, the NMPA launched the "Spring Rain Action" to facilitate clinical innovation translation into medical device products over three years. Policies are extending applications to home settings, with a November 2025 initiative promoting high-end devices, wearables, and efficient IVD tools for household health management.
Lifecycle regulation is being strengthened to balance safety and high-quality development. A January 2025 State Council directive overhauled drug and device regulation, including shortening clinical trial approval timelines for devices from 60 to 30 working days and granting priority review for medical robots, brain-computer interfaces, and high-end implants. The NMPA has also issued ten measures for optimizing special approval procedures and strengthening post-market surveillance, alongside new Good Manufacturing Practice standards issued in November 2025. Medical insurance policies are now incorporating qualifying innovative devices into reimbursement, and a March 2025 pricing guide added items for brain-computer interface services, supporting the clinical translation of these technologies.
In terms of technological progress, over 2.8 million medical equipment patent applications were filed in China in 2025, representing 34% of the global total, according to the China Medical Equipment Patent Development Trends report. This signals a shift from an imitation phase to autonomous innovation. The number of valid invention patents in medical instrument manufacturing surged from under 3,000 in 2011 to 50,500 in 2024, a CAGR of 26.37%. R&D investment intensity is particularly high in the medical equipment segment, and the expansion of R&D personnel, especially at leading firms, remains a key driver. Companies with narrow product portfolios, weak technology moats, and limited R&D capabilities, particularly those in procurement-sensitive segments, are more exposed to cyclical business fluctuations. In high-end imaging and surgical robotics, R&D investment directly determines product performance and long-term competitive positioning.
Credit and Rating Analysis
Bond financing activity in the sector is vibrant, particularly for technology innovation. As of September 4, 2026, there were 16 outstanding bonds in the medical device industry with a total balance of RMB 10.559 billion. Of these, nine were science and technology bonds with a balance of RMB 5.54 billion, accounting for over half of the total. Private enterprises are the primary issuers. Instruments include medium-term notes, convertible bonds, ultra-short-term financing bills, and private placements, with maturities predominantly exceeding one year. Proceeds are mainly used for debt refinancing and structure optimization, with limited new incremental investment. The average industry credit spread was approximately 107.4 basis points, excluding convertibles. Average spreads were 126.88 BP in 2024, 152.74 BP in 2025, and 90.19 BP from January through June 2026, reflecting a narrowing driven by structural factors and a decline in the broader pharmaceutical and biotech sector spreads. Among the nine sample issuers, credit ratings are dispersed: two entities hold AAA ratings, three hold AA+, two hold AA, and two are rated AA- or below.
Cyclical Outlook
The industry is entering a new phase of qualitative breakthroughs, propelled by the waning impact of centralized procurement and the commercial launch of innovative products. The core logic of this cycle is the reshaping of industrial value through technological innovation and domestic industrial upgrading. The long-term credit outlook remains stable, although structural risks will persist, focusing on weaker entities’ limited capacity to convert innovation into commercial success.
Supportive policies for innovation, high-end manufacturing, and industrial development are creating a conducive environment. Routine centralized procurement is driving the exit of low-end capacity and redirecting resources toward high-value, high-barrier innovation. Technological breakthroughs in surgical robotics, AI diagnostics, brain-computer interfaces, and precision interventional devices are expanding market boundaries and creating new growth curves. Synergies with AI, telemedicine, and rehabilitation care are strengthening, and AI-enabled devices are poised to enter higher-risk diagnostic and therapeutic domains. Innovation and cross-sector convergence may also address challenges of cost and infrastructure that have hindered the widespread adoption of advanced imaging in primary care settings.
However, reliance on foreign sources for core chips, precision sensors, and high-end optical components remains a vulnerability. Geopolitical frictions and rising trade protectionism increase compliance costs for domestic firms expanding internationally. These external supply constraints and intensifying internal competition are accelerating market restructuring, with benefits concentrating among leading players. Companies with integrated supply chain capabilities are solidifying their dominance, and their credit profiles are likely to remain stable. Small and medium-sized enterprises are diverging; some are developing differentiated, niche product portfolios, while those lacking core technologies and continuous innovation face consolidation or market exit. As the industry progresses from quantitative growth to qualitative breakthroughs, the primary drivers of long-term value will be technological innovation and a more resilient, higher-value domestic industrial base.
All rights reserved. The content of this publication is the property of its publisher. Any reproduction or distribution requires prior authorization. The views expressed herein are for reference only and do not constitute investment advice. Dagong International Credit Rating Co., Ltd. assumes no liability for any losses incurred from reliance on this content.